EMEND 80 mg hard capsulesaprepitant
EMEND contains the active substance aprepitant and belongs to a group of medicines called "neurokinin 1 (NK1) receptor antagonists". The brain has a specific area that controls nausea and vomiting. EMEND works by blocking the signals to this area, and thus reducing nausea and vomiting. EMEND hard capsules are used in adults and adolescents from 12 years of age, in combination with other medicinesto prevent nausea and vomiting caused by a type of chemotherapy (cancer treatment) that induces strong and moderate nausea and vomiting (such as cisplatin, cyclophosphamide, doxorubicin or epirubicin).
Do not take EMEND
Consult your doctor, pharmacist or nurse before you start taking EMEND or giving it to your child.
Before treatment with EMEND, tell your doctor if you or your child have liver disease, as the liver is important for removing the medicine from the body. Your doctor may need to monitor your liver or your child's liver.
Do not give EMEND 80 mg and 125 mg capsules to children under 12 years of age, as the 80 mg and 125 mg capsules have not been studied in this population.
EMEND may affect other medicines during and after treatment with EMEND. There are some medicines that should not be taken with EMEND (such as pimozide, terfenadine, astemizole and cisapride) or that require a dose adjustment (see also ‘Do not take EMEND’).
The effects of EMEND or other medicines may be influenced if you or your child take EMEND with other medicines, including those listed below. Consult your doctor or pharmacist if you or your child are taking any of the following medicines:
Tell your doctor or pharmacist if you or your child are taking, have recently taken or might take any other medicines.
Do not use this medicine during pregnancy unless clearly necessary. If you or your daughter are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
For information on contraception, see ‘Other medicines and EMEND’.
It is not known if EMEND passes into breast milk; therefore, breast-feeding should be avoided during treatment with this medicine. It is important to tell your doctor before taking this medicine if you or your daughter are breast-feeding or plan to breast-feed.
Some people may feel dizzy or drowsy after taking EMEND. If you or your child feel dizzy or drowsy, do not drive, ride a bicycle or use machines or tools after taking this medicine (see ‘Possible side effects’).
EMEND hard capsules contain sucrose. If your doctor has told you or your child that you or they have an intolerance to some sugars, consult your doctor before taking this medicine.
This medicine contains less than 23 mg of sodium (1 mmol) per capsule; this is essentially “sodium-free”.
Always take or give EMEND exactly as your doctor, pharmacist or nurse has told you or your child. If you are not sure, check with your doctor, pharmacist or nurse. Take EMEND always with other medicines to prevent nausea and vomiting. After treatment with EMEND, your doctor may ask you or your child to continue taking other medicines to prevent nausea and vomiting, including corticosteroids (such as dexamethasone) and a ‘5-HT3 antagonist’ (such as ondansetron). If you are not sure, check with your doctor, pharmacist or nurse.
The recommended oral dose of EMEND is:
Day 1:
Days 2 and 3:
EMEND can be taken with or without food. Swallow the capsule whole with some liquid.
Do not take more capsules than your doctor recommends. If you or your child have taken too many capsules, contact your doctor immediately.
If you or your child have missed a dose, ask your doctor for advice.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Other side effects that have been reported are listed below.
If you or your child experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in the Appendix.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month.
Store in the original package to protect from moisture. Do not remove the capsule from the blister until you are ready to take it.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
What EMEND contains
The 125 mg hard capsule is opaque with a white body and a pink cap with “462” and “125 mg” printed in a radial manner in black ink on the body.
The 80 mg hard capsule is opaque with a white body and a white cap with “461” and “80 mg” printed in a radial manner in black ink on the body.
EMEND 125 mg and 80 mg hard capsules are supplied in the following pack sizes:
Not all pack sizes may be marketed.
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
Netherlands
For further information on this medicine, contact the local representative of the Marketing Authorisation Holder:
Belgique/België/Belgien Lietuva
MSD Belgium BVBA/SPRL UAB Merck Sharp & Dohme Tel/Tel: +32(0)27766211 Tel. + 370 5278 02 47 dpoc_belux@merck.com msd_lietuva@merck.com
????????
???? ???? ? ???? ???????? ???? ???.: +359 2 819 3737 info-msdbg@merck.com
Ceská republika
Merck Sharp & Dohme s.r.o. Tel: +420 233 010 111 dpoc_czechslovak@merck.com
Danmark
MSD Danmark ApS Tlf: + 45 4482 4000 dkmail@merck.com
Deutschland
MSD SHARP & DOHME GMBH Tel: 0800 673 673 673 (+49 (0) 89 4561 2612) e-mail@msd.de
Eesti
Merck Sharp & Dohme OÜ Tel.: +372 6144 200 msdeesti@merck.com
Eλλ?δα
MSD Α.Φ.Β.Ε.Ε. Τηλ: +30 210 98 97 300 dpoc_greece@merck.com
España
Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 msd_info@merck.com
France
MSD France Tél:+33(0)1 80 4640 40
Hrvatska
Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333 croatia_info@merck.com
Ireland
Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 medinfo_ireland@merck.com
Ísland
Vistor hf. Simi: +354 535 7000
Luxembourg/Luxemburg
MSD Belgium BVBA/SPRL Tél/Tel: +32(0)27766211 dpoc_belux@merck.com
Magyarország
MSD Pharma Hungary Kft. Tel.: +36 1 888 5300 hungary_msd@merck.com
Malta
Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com
Nederland
Merck Sharp & Dohme B.V. Tel: 0800 9999000
(+31 23 5153153) medicalinfo.nl@merck.com
Norge
MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@msd.no
Österreich
Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 msd-medizin@merck.com
Polska
MSD Polska Sp. z o.o. Tel: +48 22 549 51 00 msdpolska@merck.com
Portugal
Merck Sharp & Dohme, Lda Tel: +351 21 4465700 inform_pt@merck.com
România
Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 msdromania@merck.com
Slovenija
Merck Sharp & Dohme, inovativna zdravila
d.o.o. Tel: +386 1 5204 201 msd_slovenia@merck.com
Slovenská republika
Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 dpoc_czechslovak@merck.com
Ιtalia
MSD Italia S.r.l. Tel: +39 06 361911 medicalinformation.it@merck.com
Κ?προς
Merck Sharp & Dohme Cyprus Limited Τηλ.: 800 00 673 (+357 22866700) cyprus_info@merck.com
Latvija
SIA Merck Sharp & Dohme Latvija Tel: +371 67364224 msd_lv@merck.com
Suomi/Finland
MSD Finland Oy Puh/Tel: +358 (0)9 804 650 info@msd.fi
Sverige
Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 medicinskinfo@merck.com
United Kingdom
Merck Sharp & Dohme Limited Tel: +44 (0) 1992 467272 medicalinformationuk@merck.com
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Instructions for healthcare professionals on the preparation of the oral suspension
Each box of EMEND contains a sachet with the powder for oral suspension, a 1 ml oral dispenser, a 5 ml oral dispenser, a cap, and a mixing cup. | |
| |
Check that there is no air in the oral dispenser (if there is air, remove it). | |
| |
| |
Hold the EMEND powder sachet for oral suspension upright and shake the contents down before opening the sachet.
| |
To avoid foam, do not shake the mixing cup. The mixture will be a cloudy to clear pink color. |
| |||
Check that there is no air in the oral dispenser (if there is air, remove it). Check that the oral dispenser contains the prescribed dose. | |||
Day 1 | Day 2 | Day 3 | |
EMEND oral suspension 25 mg/ml | 3 mg/kg orally Maximum dose 125 mg | 2 mg/kg orally Maximum dose 80 mg | 2 mg/kg orally Maximum dose 80 mg |
| |||
Discard any leftover suspension and materials that have come into contact with it. The disposal of unused medication and all materials that have come into contact with it will be carried out in accordance with local regulations. |